RxDoctor Payments DataLook up a doctor →

Emily Roman, PA

Physician Assistant · Fairfield, CTNPI 1700280146

Payments from drug & device makers

$12,911in general payments, 2019–2025

Across 661 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$956
  • Amgen$807
  • Pfizer$722
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$12,81499%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,911 in reported general payments places this provider in the 95th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$29,416
Medicare patients
172
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$20,343
MounjaroTirzepatide13$13,950
Tresiba Flextouch U-200Insulin Degludec14$6,774
SynthroidLevothyroxine Sodium19$2,059
Nebivolol Hcl18$1,683
Rosuvastatin Calcium78$992
Levothyroxine Sodium59$725
Omeprazole36$672
Atorvastatin Calcium116$639
Losartan Potassium61$624
Escitalopram Oxalate56$462
Amlodipine Besylate64$432
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav53$432
Metoprolol Succinate30$391
Irbesartan12$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$956$20,34315 claims
Lilly USA, LLCMounjaro$349$13,95013 claims
AbbVieSynthroid$2,277$2,05919 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$82$72559 claims
Almatica Pharma LLCSertraline Hcl$29$12215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →